Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion clinical trials

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

This study is testing a new drug, TherO2-01S22, for people with metastatic breast cancer that is HER2-positive. It aims to see how well it works and if it's safe when added to standard treatments. Researchers want to understand if it can shrink tumours.